|
|
||||||||
Division of Gastrointestinal Pathology, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322
| Abstract |
|---|
|
|
|---|
-D-xylopyranoside. These
findings implicate epithelial cell surface proteoglycans decorated with
sulfated fucose moieties as ligands for CD11b/CD18 during PMN migration
across mucosal surfaces. | Introduction |
|---|
|
|
|---|
2 integrin CD11b/CD18 (Mac-1, CR3), but not
CD11a/CD18 (3). It is generally believed that CD11b/CD18
mediates initial adhesion of PMN to epithelial monolayers by
interactions with a counter-receptor(s) on the epithelial cell surface.
The nature of these counter-receptors or adhesive ligands that play an
important role in regulating PMN transepithelial migration, however,
have not been defined. Like other
2 integrins,
CD11b/CD18 contains both an I or an A domain and a lectin-like domain
that mediate ligand specificity. An
200-aa region comprising the I
domain has been extensively characterized, revealing homology to plasma
proteins such as von Willebrand factor, complement factor II, and
extracellular matrix proteins, including collagen and cartilage matrix
protein (4, 5). It is also regarded as a major recognition
site for several ligands of CD11b/CD18 (6). While the
precise localization of the lectin-like domain on CD11b is not known,
results from a previous study suggested localization between the I
domain and C-terminal regions of CD11b (7).
The unique structure of CD11b/CD18 enables it to bind to a wide variety
of proteins and carbohydrates. Previously reported ligands for
CD11b/CD18 include cell membrane proteins such as ICAM-1 (6, 8) and soluble factors such as iC3b (9, 10),
fibrinogen (11), LPS (12, 13), elastase
(14), oligodeoxynucleotide (15), zymosan
(16),
-glucan (17), heparin (heparin
sulfate) (18, 19), denatured proteins (20),
and a hookworm-derived neutrophil adhesion inhibitor (21).
While ICAM-1 is the only cell membrane protein ligand that has been
reported for CD11b/CD18 and has been shown to play an important role in
PMN transendothelial migration, it does not appear to play a role in
PMN migration across intestinal epithelium. In particular, ICAM-1
expression is induced on the apical membrane of intestinal epithelial
cells only under certain inflammatory conditions (3, 22).
Under these conditions apically expressed ICAM-1 is not accessible as a
ligand for migrating PMN, because transepithelial migration is
dependent on interactions of PMN with the basolateral membrane of
intestinal epithelial cells. These observations argue against a role
for ICAM-1 as an adhesive ligand for PMN during transepithelial
migration in the intestine. Previous studies have also suggested that
heparin binds to CD11b/CD18 (18, 19). It was proposed that
epithelial cell surface proteoglycans decorated with heparin sulfate
moieties (HSPGs) might serve as adhesive ligands for CD11b/CD18.
However, no such HSPGs have yet been identified. Furthermore,
syndecan-1, a heparan sulfate proteoglycan that is expressed primarily
on epithelial cells, does not support PMN adhesion
(18).
Lectin-like properties of CD11b/CD18 have been borne out by several reports demonstrating carbohydrate binding to CD11b/CD18 (7, 16, 18). However, the role of epithelial cell surface carbohydrates in CD11b/CD18-mediated adhesive interactions has not been characterized. Previously, it was shown that certain carbohydrates, such as mannose-6-phosphate, glucose-6-phosphate, heparin, and fucoidin, are effective inhibitors of PMN migration across T84 cell monolayers (23). These results strongly suggested that carbohydrates play a role in regulating PMN transepithelial migration. However, the mechanism by which these carbohydrates regulate PMN transepithelial migration and demonstration of their existence on the epithelial cell surface have not been reported.
In the present study we tested a wide range of mono- and polysaccharides for inhibition of epithelial T84 cell adhesion to purified CD11b/CD18. We demonstrate that several carbohydrates, including fucoidin, heparin/heparin sulfate, N-acetyl-D-glucosamine, mannose-6-phosphate, and laminarin, can significantly inhibit the adhesion of T84 cells to purified CD11b/CD18. We have determined that fucoidin is the most potent inhibitor of cell adhesion and does so by binding to CD11b/CD18 in a divalent cation-dependent fashion. We also determined the role of cell surface fucose moieties and fucosylated proteoglycans in regulating T84 cell adherence to CD11b/CD18. We show that fucosylated proteins derived from solubilized intestinal epithelial cells via the fucose-specific lectin column contain several candidate CD11b/CD18 binding proteins. Based on these results we conclude that epithelial T84 cell surface proteoglycans decorated with sulfated fucose moieties serve as adhesive ligands for CD11b/CD18 during the transmigration response.
| Materials and Methods |
|---|
|
|
|---|
T84 intestinal epithelial cells were grown in a 1/1 mixture of
DMEM and Hams F-12 medium supplemented with 15 mM HEPES buffer (pH
7.5), 14 mM NaHCO3, 40 µg/ml penicillin, 8
µg/ml ampicillin, 90 µg/ml streptomycin, and 5% newborn calf serum
(Life Technologies, Gaithersburg, MD). The fluorescent probe
2',7'-bis-(2-carboxyethyl)-5-(and -6)-carboxyfluorescein acetoxymethyl
ester (BCECF-AM) was purchased from Molecular Probes (Eugene, OR). The
glycosidase
-L-fucosidase from bovine kidney (EC
3.2.1.51) and neuraminidase (sialidase) from arthrobacter ureafaciens
(EC 3.2.1.18), which cleaves both
2,3- and
2,6-linked sialic acid
(24), were obtained from Roche (Indianapolis, IN).
Biotin-
-aminocaproic acid N-hydroxysuccinimide ester
(biotin-X-NHS), heparin (from porcine intestinal mucosa;
Mr = 13,00015,000), and heparan sulfate (from
bovine intestinal mucosa; Mr = 7, 500) were
purchased from Calbiochem (La Jolla, CA). Other mono- and
polysaccharides, including fucoidin, dextran
(Mr = 428,000), dextran sulfate
(Mr = 500,000), mannose-6-phosphate,
glucose-6-phosphate, chondroitin sulfate C (from shark cartilage),
galactose, L-fucose, and laminarin were purchased
from Sigma (St. Louis, MO). FITC-labeled lectin from tetragonolobus
purpureas, tetragonolobus purpureas immobilized on 4% beaded agarose,
and an anion exchanger (Dowex H+ 50 WX8-100) were
also obtained from Sigma. A panel of functionally characterized mAbs
that had been previously shown to bind to the defined regions of the
CD11b extracellular domain (18, 25) was used as purified
IgG. This panel of mAbs included CBRM1/23 (C domain binding, IgG2a),
CBRM1/29 (I domain binding, IgG1), CBRM1/31 (I domain binding, IgG1),
LM2/1 (I domain binding, purified IgG1), and OKM1 (C domain binding,
IgG2b). A rabbit polyclonal Ab against human CD11b R7928A was raised by
immunizing rabbit with a peptide (DMMSEGGPPGAEPQ) corresponding to the
C terminus of CD11b as previously described (26).
Hybridoma cells secreting a functionally inhibitory mAb against CD18
(TS1/18, IgG1) were purchased from American Type Culture Collection
(Manassas, VA). A protease inhibitor mixture consisting of soybean
trypsin inhibitor, benzamidine, leupeptin, pepstatin A, bestatin, and
aprotinin was obtained from Calbiochem. GelCode Blue stain Reagent was
obtained from Pierce (no. 24590; Rockford, IL). Nitrocellulose membrane
and pre-stained m.w. markers were purchased from Bio-Rad (Richmond,
CA). All other reagents, unless stated, were obtained from Sigma.
Purification of CD11b/CD18
Functionally active CD11b/CD18 was purified to homogeneity from
large quantities of human PMN (
1010 cells) by
immunoaffinity chromatography using LM2/1-Sepharose, as previously
described by Diamond et al. (8). SDS-PAGE of the purified
integrin, followed by Coomassie blue staining, revealed two prominent
protein bands with Mr of
150 and 95 kDa,
characteristic of CD11b and CD18, respectively (not shown). The typical
yield of CD11b/CD18 from 1010 PMN ranged from 1
to 2 mg.
T84 cell adhesion to purified CD11b/CD18
T84 cell adhesion to immobilized, purified CD11b/CD18 was
performed as previously described (25). Briefly, purified
CD11b/CD18 (
100 µg/ml in 150 mM NaCl, 2 mM
MgCl2, 2 mM CaCl2, 100 mM
Tris, and 1%
N-octyl-
-D-glucopyranoside, pH 7.4)
was diluted 20-fold with HBSS and immediately added to 96-well,
flat-bottom, microtiter plates (ICN Biomedical, Aurora, OH; 50
µl/well). Microtiter plates were kept at 4°C overnight to allow for
protein binding. Nonspecific protein binding was blocked by adding 1%
BSA in HBSS solution for 1 h at room temperature.
Trypsin/EDTA-elicited T84 cells were then washed twice with HBSS and
incubated with 5 µg/ml BCECF-AM (Molecular Probe) in HBSS for 15 min
at 37°C. After washing by centrifugation, fluorescence-labeled T84
cells were added to CD11b/CD18-coated plates
(
2.5x105 cells/well in a total volume of 150
µl), followed by stationary incubation at 37°C for 1 h to
allow for cell adhesion. To quantify adhesion, plates were gently
washed three times, and the fluorescence of each well was determined
using a fluorescence microtiter plate reader at excitation/emission
wavelengths of 485/535 nm (Millipore, Milford, MA). Cell
adherence was calculated as the percentage of total applied cells:
100 x (postwash fluorescence/pre-wash fluorescence). In some
experiments, T84 cells were pretreated with test compounds/mAbs as
indicated before addition to CD11b/CD18-coated wells.
Biochemical modification of fucoidin
Desulfation of fucoidin was achieved by solvolysis in dimethylsulfoxide as previously described (27). Briefly, the sodium salt of fucoidin (250 mg) was converted into free acid using Dowex 50 W-X8 (H+) (Sigma), neutralized with pyridine, and lyophilized. The pyridinium salt was then dissolved in 10 ml of 10% aqueous Me2SO. The solution was heated at 80°C for 90 min and cooled in an ice bath. The reaction mixture was diluted to 20 ml with water, and the pH was adjusted to 9.0 using 0.1 M NaOH. The mixture was then dialyzed and lyophilized.
Fucoidin (normal and desulfated) was biotinylated using biotin-X-NHS after cyanogen bromide activation and aminoalkylation with diaminohexane. This method has been shown to effectively label polysaccharides while preserving the polysaccharide structure (28). Briefly, 500 mg of polysaccharide was mixed with 875 mg of cyanogen bromide in 28 ml of 0.5 M Na2CO3 solution (pH 11) with vigorous stirring for 30 min. Activated carbohydrates were de-salted over a Sephadex G-50 column and mixed with 750 mg of diaminohexane in 15 ml of 0.4 M NaHCO3 solution (pH 9.5). The mixture was gently stirred at 4°C for 14 h and dialyzed against PBS. After lyophilization, 200 mg of aminoalkyl derivative dissolved in 100 ml of 0.1 M NaHCO3 (pH 8.0) was reacted with 27 mg of biotin-X-NHS (Calbiochem). After 6 h at 25°C the solution was extensively dialyzed. The biotinylated aminoalkyl derivatives were recovered by lyophilization.
Fucoidin-CD11b/CD18 binding assay
The binding of fucoidin to CD11b/CD18 was studied using two
reciprocal methods. First, to assay binding of biotinylated fucoidin to
immobilized CD11b/CD18, purified CD11b/CD18 was diluted (
20-fold)
with HBSS and bound to 96-well, flat-bottom, microtiter plates as
described above. After blocking with 2% BSA in HBSS, biotinylated
fucoidin (10 µg/ml) was added (37°C, 30 min). Plates were washed
three times with HBSS containing 0.5% BSA and then incubated with
HRP-conjugated streptavidin in HBSS containing 2% BSA for 30 min at
room temperature. Polysaccharide/CD11b complexes were detected
colorimetrically using ABTS. Controls included BSA-coated wells or
wells without fucoidin (streptavidin alone). As a reciprocal method,
CD11/CD18 was assayed for binding to immobilized fucoidin. Here, 100
µl of fucoidin (5 mg/ml) in HBSS was added to microtiter wells,
followed by incubation for 2 h at 37°C. After washing off
unbound fucoidin, fucoidin-coated wells were blocked with 2% BSA in
HBSS for 1 h at room temperature. Purified CD11b/CD18 (5 µg/ml)
in HBSS containing 0.1% Triton X-100 was added to the fucoidin-coated
wells. After 1-h incubation at 37°C, the plates were washed three
times with HBSS containing 0.1% Triton X-100, followed by incubation
with anti-CD18 mAb TS1/18 (1/500 dilution) or polyclonal Ab R7928A
(1/200 dilution) in HBSS containing 2% BSA. After washing away unbound
Ab, wells were incubated with HRP-conjugated secondary Ab, followed by
addition of substrate (ABTS) for color development and OD measurement.
Wells coated with BSA (no fucoidin) or chondroitin sulfate C served as
controls.
Neoproteoglycan preparation and CD11b/CD18 binding experiments
A neoproteoglycan derivative of fucoidin was prepared according to the method described by Matsumoto et al. (29). Briefly, 30 mg of fucoidin was dissolved in 4 ml of distilled water and mixed with 30 mg of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in 6 ml of ethanol. After preincubation at room temperature for 2 h, 60 mg of BSA was added, and the mixture was incubated at 4°C for 2 days with gentle shaking. The mixture was then dialyzed against PBS, followed by lyophilization and storage at 4°C for further use. The formation of neoproteoglycan was confirmed by SDS-PAGE, demonstrating a shift in the m.w. of BSA under nonreducing conditions. To test the binding of fucoidin neoproteoglycan to CD11b/CD18, fucoidin neoproteoglycan (fucoidin-BSA conjugate) and BSA (control) were subjected to SDS-PAGE analysis on a 415% gradient gel (5 µg/lane). Proteins were directly visualized with silver staining or were electrophoretically transferred onto nitrocellulose filter (Bio-Rad, Richmond, CA), followed by probing with CD11b/CD18. To probe with CD11b/CD18, nitrocellulose filters were first incubated with blocking solution (HBSS containing 0.2% Triton X-100 and 1% BSA) for 1 h at room temperature. The filters were then incubated with purified CD11b/CD18 (final concentration, 510 µg/ml) in blocking solution for 2 h at 37°C. After washing filters with HBSS containing 0.1% Triton X-100 (three times for 510 min each time), nitrocellulose filters were incubated sequentially with anti-CD18 mAb TS1/18 (1/1000 dilution) and HRP-conjugated secondary Ab, followed by detection with ECL. All reactions were performed in the presence of 2 mM Mg2+ and Ca2+.
Probing T84 cell fucose residue-containing proteins with CD11b/CD18
Isolation of fucosylated proteins from detergent lysate of T84
cells was performed using a fucose-specific lectin column. Briefly, T84
cells (
4 x 109) were harvested with
trypsin/EDTA and lysed with 3035 ml of lysis buffer containing 100 mM
Tris, 150 mM NaCl, 2.5 mM CaCl2, 2.5 mM
MgCl2, 1% Triton X-100, and a mixture of
proteinase inhibitors, pH 7.3. After a 1-h high speed (45,000 x
g) centrifugation, the cell lysate supernatant was pumped
through a fucose-specific lectin column (tetragonolobus purpureas) at
810 ml/h. After extensive washing with HBSS containing 0.1% Triton
X-100, the column was then eluted with a solution of 200 mM Tris, 50
mg/ml
-L-fucose, and 0.8% SDS, pH 9.5. The
protein collection was immediately neutralized with 1.5 M Tris buffer
(pH 7.2), dialyzed extensively against HBSS using 10-kDa cut-off
dialysis bag, and concentrated before further analysis. Purified
proteins were analyzed by SDS-PAGE (10 µg/lane), followed by either
direct GelCode Blue staining or CD11b/CD18 probing after transfer onto
nitrocellulose filters as described above.
Cell surface deglycosylation experiments
Removal of T84 cell surface fucose residues was performed as described by Brennan et al. (24) with slight modifications. Briefly, trypsin/EDTA-elicited T84 cells (5 x 105 cell/ml) were incubated at 37°C for different lengths of time with fucosidase (0.1, 0.5, and 1.0 U/ml) in PBS containing 2.5 mM EDTA, 1 mM benzamidine, and 10 µg/ml each of PMSF and pepstatin A, pH 7.0. Cells were then washed with cold HBSS before BCECF-AM labeling with BCECF-AM and cell adhesion assays. To remove T84 cell surface sialic acid residues, trypsin/EDTA-elicited cells were incubated with neuraminidase (0.1, 0.5, and 1.0 U/ml) in PBS (pH 7.0) containing 2.5 mM EDTA, 1 mM benzamidine, and 10 µg/ml each of PMSF and pepstatin A at 37°C for different lengths of time. Cells were then washed with cold HBSS before BCECF-AM labeling and use in adhesion assays. Controls included cells incubated in the same buffers and conditions, but without enzymes. Trypan blue exclusion was assessed to verify cell viability after enzyme treatment.
Cell surface staining with fucose-specific lectin
Cell surface staining with fucose-specific lectin was performed as previously described (30). Trypsin/EDTA elicited T84 cells were washed three times with cold HBSS and then blocked with HBSS containing 5% FCS for 1 h at room temperature. Cells (5 x 105/ml) were then incubated with FITC-conjugated fucose-specific lectin from tetragonolobus purpureas (final concentration, 20 µg/ml) in HBSS containing 5% FCS for 30 min at room temperature. Cells were washed three times with HBSS, shortly fixed with 1% paraformaldehyde (15 min), washed twice with HBSS, mounted on slides, and observed under a fluorescence microscope. In this experiment T84 cells were also treated with 1.0 U/ml fucosidase at 37°C for 1 h before labeling with FITC-lectin.
Blockage of T84 cell proteoglycan synthesis
Biosynthesis of proteoglycans was blocked in T84 cells as
previously described (31). T84 cells in 12-well tissue
culture plates (
75% confluence) were grown in cell culture medium
(1:1 mixture of DMEM and Hams F-12 medium in 5% dialyzed FCS)
containing 2 mM
p-nitrophenyl-
-D-xylopyranoside
(
-xy) overnight (37°C, 5% CO2). As a
control, T84 monolayers were incubated in cell culture medium
containing 2 mM
p-nitrophenyl-
-D-xylopyranoside
(
-xy), which does not inhibit biosynthesis of cell proteoglycans.
T84 cell monolayers were washed twice with cell culture medium before
harvesting, labeling with BCECF-AM, and used in cell adhesion assays.
In some experiments cells were also treated with a combination of
fucosidase and 2 mM
-xy. The cells that were grown in the presence
of 2 mM
-xy were harvested with trypsin/EDTA and further incubated
with fucosidase (1.0 U/ml) in PBS containing 2.5 mM EDTA, 1 mM
benzamidine, and 10 µg/ml each of PMSF and pepstatin A for 60 min at
37°C. After washing with cold HBSS, cells were labeled with BCECF-AM
in HBSS and assayed for adhesion to immobilized CD11b/CD18. Trypan blue
exclusion was assessed to ensure cell viability.
Statistics
Data are presented as the mean ± SD and were compared by Students t test.
| Results |
|---|
|
|
|---|
We tested a wide variety of carbohydrates for inhibition of
epithelial cell adhesion to purified CD11b/CD18. We previously
demonstrated that purified CD11b/CD18 immobilized in microtiter wells
supported binding of 3055% of the total applied T84 cell load after
1 h of incubation at 37°C, while <5% of applied cells adhered
to wells coated with BSA alone (25). Complete inhibition
of T84 cell adhesion to CD11b/CD18 by mAb CBRM1/29 demonstrates the
specificity of this interaction. Table I
represents a summary of the effects of a panel of carbohydrate moieties
on T84 cell adhesion to CD11b/CD18. As shown, among all carbohydrates
tested, fucoidin potently inhibited adhesion in a
concentration-dependent fashion. At a low concentration of 0.1 mg/ml,
fucoidin significantly inhibited cell-integrin adhesion (79.3 ±
6.8% inhibition; p < 0.001). Adhesion of T84
cells to CD11b/CD18 was also significantly reduced by heparin
(46.5 ± 8.1% inhibition; p < 0.03), heparin
sulfate (43.2 ± 9.4% inhibition; p < 0.03),
N-acetyl-D-glucosamine (40.8 ±
10.2% inhibition; p < 0.03), mannose-6-phosphate
(38.5 ± 6.4% inhibition; p < 0.03), and
laminarin (39.7 ± 11.3%; p < 0.03), but only at
high concentration (10 mg/ml). However, no significant inhibition was
found in the presence of glucose-6-phosphate, dextran, dextran sulfate,
chondroitin sulfate C, L-fucose, or galactose.
Unlike fucoidin, which is a polymer of sulfated
L-fucose, the monosaccharide
L-fucose had no effect on T84 cell adhesion to
CD11b/CD18. As shown in Fig. 1
, 50%
inhibition of T84 cell binding to CD11b/CD18 was observed at fucoidin
concentrations of 15 x 10-8 M.
|
|
|
The cell adhesion results suggested the possibility of binding
interactions between fucoidin and CD11b/CD18, and additional
experiments were performed to examine this possibility. The binding of
fucoidin to CD11b/CD18 was investigated using two reciprocal binding
assays: biotinylated fucoidin binding to immobilized CD11b/CD18 and
CD11b/CD18 binding to immobilized fucoidin. For the first assay
fucoidin was biotinylated (28) and added to
CD11b/CD18-coated microtiter wells. After incubation at 37°C for
1 h, bound fucoidin was detected with HRP-streptavidin and color
development. We observed that biotinylated fucoidin bound to
CD11b/CD18, but not to BSA (Fig. 3
A). In the reciprocal assay
microtiter wells were first coated with unlabeled fucoidin, followed by
addition of purified CD11b/CD18 in buffer containing
Mg2+ and detergent. CD11b/CD18 binding was then
detected with anti-CD18 Ab (TS1/18), HRP-conjugated goat
anti-mouse secondary Ab, and color development. As shown in Fig. 3
B, CD11b/CD18 bound to fucoidin-coated wells; in contrast,
there was little binding of CD11b/CD18 to either BSA-coated wells or
chondroitin sulfate C-coated wells.
|
|
A modified Western blotting protocol was employed using purified
CD11b/CD18 as a probe to evaluate binding to synthetic
fucoidin-containing neoproteoglycans. For these experiments a
BSA-fucoidin conjugate (BSA-F) was prepared as previously described
(29) with minor modifications. SDS-PAGE of BSA-F
demonstrated a large shift in the molecular mass of the complex to a
higher apparent molecular mass on a 415% gradient gel (Fig. 5
A, lane 1)
compared with normal BSA alone (Fig. 5
A, lane 2).
Fig. 5
B represents a modified Western blot in which samples
of BSA-F (lane 1) and BSA (lane 2)
were subjected to SDS-PAGE and transferred to nitrocellulose filters,
followed by incubation with CD11b/CD18 in the presence of 2 mM
Mg2+ and detergent at room temperature. Bound
CD11b/CD18 was detected by probing washed blots with anti-CD18 mAb
(TS1/18) and HRP-conjugated secondary Ab, followed by ECL. As shown in
Fig. 5
B, a strong CD11b/CD18 binding signal was detected in
BSA-F (lane 1), but was completely absent in the BSA
control (lane 2).
|
Sulfation of polysaccharides has been shown to be important for a
number of glycosylated proteins (proteoglycans) interacting with
integrins (32, 33, 34). Thus, experiments were performed to
examine whether sulfation of fucoidin plays a role in binding to CD11b.
For these experiments fucoidin was chemically desulfated, followed by
biotinylation before use in binding assays with CD11b/CD18. The
desulfation method we used in the experiments did not destroy the
polymer structure of fucoidin and resulted in 75%90% desulfation of
fucoidin polysaccharide. As shown in Fig. 6
A, the binding of desulfated
fucoidin to immobilized CD11b/CD18 was diminished by 65% compared with
that observed with untreated fucoidin. In Fig. 6
B,
desulfated fucoidin was also tested for inhibition of T84 cell adhesion
to purified CD11b/CD18. As shown, binding of T84 cells to CD11b/CD18 in
the presence of 10 mg/ml of desulfated fucoidin was only mildly
inhibited (
25% decrease), whereas binding in the presence of
untreated fucoidin was reduced by 95%.
|
To determine whether epithelial cell surface fucosylation plays a
role in adhesion to CD11b/CD18, T84 cells were treated with fucosidase
and assayed for adhesion. For these experiments trypsin/EDTA-elicited
T84 cells were labeled with BCECF, followed by incubation with
different amounts of fucosidase at 37°C. As a control, parallel
experiments were performed in which cells were incubated with
neuraminidase to remove cell surface sialic acid residues. The
enzyme-treated cells were still 95% viable based on trypan blue
exclusion 2 h after enzymatic treatments. Fucosidase treatment
significantly reduced T84 cell adhesion to CD11b/CD18 in a
concentration- and time-dependent fashion (Fig. 7
). In contrast, no significant
inhibition was observed after pretreatment of cells with neuraminidase.
These results suggest that T84 cells contain cell surface fucose-like
structures that partially mediate binding to CD11b/CD18.
|
|
Since the above results and those reported previously (35, 36) confirm the existence of fucose residues on the epithelial
cell surface, we reasoned that inhibition of the synthesis of cell
surface proteins decorated with such residues might influence adhesive
interactions with CD11b/CD18. Candidate cell surface molecules
containing fucose moieties include glycolipids and proteoglycans that
are decorated with sulfated fucose polymers. To inhibit proteoglycan
synthesis, T84 cell monolayers were cultured overnight in the presence
of 2 mM
-xy, followed by labeling and use in cell adhesion assays.
As a control, parallel incubations were performed in the presence of 2
mM
-xy, which does not inhibit proteoglycan synthesis. In both
conditions cell viability was >95% after treatment as assessed by
trypan blue exclusion. As shown in Fig. 9
, treatment of T84 cells with
-xy had
no significant effect on cell adhesion to CD11b/CD18 compared with
untreated cells (52.5 ± 6.7 vs 51.7 ± 5.9% of total
applied cells adhering to CD11b/CD18 for
-xy vs no drug treatment,
respectively). In contrast, adhesion of
-xy-treated T84 cells to
purified CD11b/CD18 was significantly reduced compared with that of
-xy-treated cells (33.4 ± 4.8 vs 52.5 ± 6.7% of applied
cells adhering to CD11b/CD18 for
-xy vs
-xy, respectively).
Interestingly, incubation of
-xy-treated T84 cells with fucosidase
(1.0 U/ml, 60 min, 37°C) did not result in further significant
inhibition of adhesion to CD11b/CD18.
|
Experiments were performed to identify fucosylated protein(s) in
T84 cells that bind to CD11b/CD18. As detailed in Materials and
Methods, fucose-containing proteins were first purified from T84
cells using a fucose-specific lectin column (tetragonolobus purpureas
immobilized on 4% beaded agarose). The mixture of fucosylated proteins
was dialyzed, concentrated, and separated by SDS-PAGE (12% gel
concentration). Proteins were also transferred to nitrocellulose
filters for our modified Western blot analysis (probing filters with
purified CD11b/CD18 protein in the presence of
Mg2+ and detergent). In our experiment,
800
µg of total fucosylated proteins were isolated from
4 x
109 T84 cells. As shown in Fig. 10
, CD11b/CD18 recognized several major
bands at Mr of 95, 50, 30, 25, and 20 kDa
(lane 3, arrowheads). Those protein bands were absent
in the control experiment in which no CD11b/CD18, but only
anti-CD18 mAb and HRP-conjugated secondary mAb, was used (Fig. 10
, lane 2). The same amount of all fucosylated proteins from
T84 cells was displayed by staining with GelCode Blue (Fig. 10
, lane 1).
|
| Discussion |
|---|
|
|
|---|
2 integrin CD11b/CD18 plays a key role in
mediating the initial stage of transepithelial migration consisting of
PMN adhesion to the basolateral epithelial surface (25, 37, 38, 39). In the present study we have further characterized the
interaction of carbohydrates with CD11b/CD18 and demonstrated a role of
fucosylated proteoglycans in CD11b/CD18-mediated epithelial cell
adhesion. In a previous study we reported that several sulfated polysaccharides, including fucoidin, inhibited PMN transepithelial migration (23). Since these experiments consisted of cell-cell adhesion and transmigration assays, the molecular mechanisms of the carbohydrate-mediated inhibition observed were not clear. The present study was undertaken to better define the mechanism of carbohydrate-mediated inhibition of transepithelial migration and the nature of epithelial ligands for migrating PMN. Here, using assays of T84 cell adhesion to highly purified CD11b/CD18, we screened a wide range of mono- and polysaccharides and identified several carbohydrates that significantly inhibit such adhesive interactions. We found that the sulfated, L-fucose-rich polysaccharide fucoidin is the most potent inhibitor (>90% inhibition) and produces 50% inhibition at a concentration of 15.0 x 10-8 M. Using a number of binding assays, we determined that fucoidin binds directly and specifically to CD11b/CD18.
The CD11b/CD18 binding properties of fucoidin are similar to those of
L-selectin, which has also been shown to bind fucoidin (40, 41). In particular, fucoidin binds to the lectin-like domain of
L-selectin with properties characteristic of C-type lectin-carbohydrate
binding interactions. CD11b also has a lectin-like domain that is most
likely present between the I domain and C-terminal regions of the
extracellular domain (7, 16). Our results indicate that
the binding of fucoidin to CD11b/CD18 is divalent cation dependent,
which is a major binding property of C-type lectins. The similarity of
carbohydrate binding patterns between CD11b/CD18 and selectin have also
been demonstrated in other cases. For example, heparin and complement
factor H have been shown as ligands for both integrins (13, 18, 19, 42, 43). We have attempted to map the fucoidin binding site
on CD11b/CD18 using anti-CD11b mAbs with defined epitopes. Since
fucoidin binding to CD11b/CD18 was strongly inhibited by I domain and
C-terminal mAbs (Fig. 4
), it is likely that fucoidin binds to a range
of sites on CD11b/CD18. Interestingly, in assays of PMN transepithelial
migration and T84 cell adhesion to purified CD11b/CD18, it is clear
that the I domain is the most critical functional binding domain
(25). Furthermore, mAb TS1/18, which binds to CD18,
strongly inhibits T84 cell binding to CD11b/CD18, but has no effect on
fucoidin binding to CD11b/CD18, suggesting that the fucoidin binding
site is localized on CD11b. Despite these differences, fucoidin is a
potent inhibitor of PMN transepithelial migration
(23).
The binding of fucoidin to CD11b/CD18 was determined to be strongly
dependent on the degree of sulfation and polymer structure. As shown in
Table I
, the monosaccharide L-fucose does not affect
cell-CD11b/CD18 adhesion, nor does D-fucose even at
concentrations as high as 20 mM (data not shown). The functional
activity of fucoidin in our CD11b/CD18 binding assays was significantly
reduced by desulfation, suggesting a critical role of sulfation in
fucoidin-CD11b/CD18 interactions. One explanation for this observation
would be that basic amino acid residues in CD11b play a role in binding
to sulfated fucans, as reported for other adhesion proteins
(44). However, other sulfated polysaccharides, such as
chondroitin sulfate C and dextran sulfate, with comparable charge
densities and m.w. did not inhibit T84 cell binding to CD11b/CD18.
These observations suggest that sulfation of fucoidin may play an
important role in modifying or maintaining the structure necessary for
binding to CD11b/CD18 instead of simple charge contributions. This
hypothesis is further supported by our finding that neuraminidase
treatment of T84 cells, which results in removal of negatively charged
sialic acid residues, did not reduce adhesion to CD11b/CD18.
Interestingly, CD18 contains a basic amino acid domain that has been
implicated in carbohydrate binding interactions (45).
While we only tested one CD18-reactive mAb TS1/18, we failed to detect
inhibition with this function blocking mAb.
As a ligand for L-selectin (40, 41) or the scavenger receptor (46, 47), fucoidin has been implicated in a wide range of physiological events, including lymphocyte tethering and rolling (48) and phagocytosis (47, 49). A role for fucoidin in cell adhesion has also been reported. In particular, bovine sperm binding to oviductal epithelium has been shown to be dependent on fucose residues (50) and can be abolished by treatment of the epithelium with fucosidase (36). Fucoidin and other sulfated polysaccharides have also been shown to be involved in sperm-egg interactions in birds (30). In vitro studies of human cells have shown that sulfated polysaccharides, including fucoidin, can inhibit lymphocyte-to-epithelial transmission of HIV-1 (51, 52). Furthermore, others have reported that adhesion of both T and B lymphocytes to cultured fibroblasts was strongly inhibited by fucoidin, whereas fucose and mannan had no effect (53). These results are in agreement with our observations and support the functional relevance of fucoidin in epithelial cell interactions with CD11b/CD18. It is possible that such interactions might be exploited therapeutically. For example in animal models, cellular infiltrates associated with meningitis can be reduced by infusion of fucoidin (22). Whether fucoidin could be used to inhibit neutrophil transepithelial migration in ulcerative colitis or Crohns disease remains to be determined.
While the nature of fucoidin-like epithelial counter-receptors for
CD11b/CD18 remains undefined, candidate structures have been reported
on epithelial cell surface (35, 54). In particular, there
are a number of structures on the epithelial cell surface that contain
fucose residues, including glycolipids, membrane glycoproteins with
terminal fucosylation, and cell surface proteoglycans decorated with
fucose or sulfated fucose sugar chains. Our data suggest that
intestinal epithelial cell surface proteoglycans decorated with
sulfated fucose polymers play an important role in CD11b/CD18-mediated
adhesive interactions. This is consistent with our finding that
blockage of biosynthesis of epithelial cell proteoglycans by
-xy
reduced T84 cell adhesion to CD11b/CD18 by the same amount observed
after treatment with
-fucosidase (Fig. 9
). While the exact
identities of such proteoglycans are not known, we have identified
several candidate fucosylated proteins that can bind to CD11b/CD18. Due
to the material (whole cell lysates from epithelial cells) we used in
purification, it is possible that some of these fucosylated proteins
recognized by CD11b/CD18 are not expressed on the cell surface. Further
characterization, including use of purified epithelial cell plasma
membranes or selective cell surface labeling with tagged lectin as
starting material, will facilitate identification of the subset of
epithelial cell surface proteoglycans that serves as adhesive ligand
for CD11b/CD18.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Ke Zen, Department of Pathology and Laboratory Medicine, Emory University, Whitehead Biomedical Building, Room 115, 615 Michael Street, Atlanta, GA 30322. E-mail address: kzen{at}emory.edu ![]()
3 Abbreviations used in this paper: PMN, polymorphonuclear leukocytes; BCECF-AM, 2',7'-bis-(2-carboxyethyl)-5-(and -6)-carboxyfluorescein, acetoxymethyl ester; biotin-X-NHS, biotin-
-aminocaproic acid N-hydroxysuccinimide ester; BSA-F, BSA-fucoidin conjugate; HSPG, heparin sulfate proteoglycan;
-xy, p-nitrophenyl-
-D-xylopyranoside;
-xy, p-nitrophenyl-
-D-xylopyranoside. ![]()
Received for publication June 19, 2002. Accepted for publication August 30, 2002.
| References |
|---|
|
|
|---|
2 integrin CR3 (CD11b/CD18) is essential for ligand binding. Cell 72:857.[Medline]
-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J. Immunol. 162:2281.
subunit and localization of a ligand recognition site to the I domain. J. Immunol. 152:4582.[Abstract]
M
2 (CD11b/CD18). J. Immunol. 160:4057.
M
2) and modulates polymorphonuclear leukocyte adhesion. J. Exp. Med. 184:1213.
-Glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J. Immunol. 163:3045.
v
3 binds to denatured collagen type I through RGD sites. Biochem. Biophys. Res. Commun. 182:1025.[Medline]
2 integrin CR3 (CD11b/CD18) is a receptor for the hookworm-derived neutrophil adhesion inhibitor NIF. J. Cell Biol. 127:2081.
precursor protein are ligands for the class A scavenger receptor. J. Biol. Chem. 276:30655.
-hydroxy aldehyde-modified low density lipoprotein by macrophage scavenger receptors. J. Lipid Res. 41:1054.This article has been cited by other articles:
![]() |
K. Zen, C. X.-J. Chen, Y.-T. Chen, R. Wilton, and Y. Liu Receptor for Advanced Glycation Endproducts Mediates Neutrophil Migration across Intestinal Epithelium J. Immunol., February 15, 2007; 178(4): 2483 - 2490. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C CHIN and C. A PARKOS Neutrophil Transepithelial Migration and Epithelial Barrier Function in IBD: Potential Targets for Inhibiting Neutrophil Trafficking. Ann. N.Y. Acad. Sci., August 1, 2006; 1072: 276 - 287. [Abstract] [Full Text] [PDF] |
||||